Semi-Solid CDMO Market to Grow with a CAGR of 10.85% through 2029

Increasing Demand for Semi-Solid Formulations and Rising Incidence of Chronic Diseases are expected to drive the Global Semi-Solid CDMO Market growth in the forecast period, 2025-2029

According to TechSci Research report, “Semi-Solid CDMO Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029F”, the Global Semi-Solid CDMO Market stood at USD 30.98 Billion in 2023 and is anticipated to grow with a CAGR of 10.85% in the forecast period through 2029.

Pharmaceutical companies are increasingly outsourcing their development and manufacturing processes to Contract Development and Manufacturing Organizations (CDMOs) to concentrate on core competencies such as research and development (R&D) and marketing. This outsourcing strategy allows companies to reduce operational costs, mitigate risks, and enhance scalability. As more firms recognize the strategic benefits of partnering with CDMOs, the demand for semi-solid manufacturing services is anticipated to rise.

Continuous advancements in drug formulation technology have significantly improved the efficacy and stability of semi-solid products. Techniques such as nanotechnology, enhanced emulsification processes, and innovative delivery systems facilitate the development of more effective and patient-friendly formulations. CDMOs that invest in cutting-edge technology and facilities are well-positioned to meet the evolving requirements of pharmaceutical companies, thereby gaining a competitive edge in the market. Regulatory agencies are increasingly establishing clear and supportive pathways for the approval of semi-solid formulations. Initiatives aimed at streamlining the regulatory process help expedite the development and market entry of new products, encouraging pharmaceutical companies to explore semi-solid formulations and driving demand for CDMO services.

The industry is also experiencing a shift towards personalized medicine, wherein treatments are tailored to individual patient needs. Semi-solid formulations are particularly advantageous in this context, as they allow for adjustments in dosages and active ingredients based on patient-specific factors. This trend is prompting pharmaceutical companies to collaborate with CDMOs that can facilitate the development of customized semi-solid products. As environmental concerns grow, there is an increasing emphasis on sustainability within the pharmaceutical sector. CDMOs that prioritize eco-friendly manufacturing practices and sustainable sourcing of ingredients are likely to attract clients seeking to enhance their corporate social responsibility (CSR) profiles. This shift towards sustainable practices not only meets consumer demand but also positions CDMOs as leaders in an evolving market landscape.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Semi-Solid CDMO Market”

The Global Semi-Solid CDMO Market is segmented into route of administration, product, service, end user, regional distribution, and company.

Based on product, the creams and lotions segment has emerged as the predominant market leader, The formulation of creams and lotions allows for the incorporation of various active pharmaceutical ingredients (APIs), including anti-inflammatory agents, antimicrobial agents, and moisturizers. This versatility enables the development of targeted therapies for diverse conditions, such as acne, eczema, and psoriasis. The ability to tailor the texture and viscosity of creams and lotions caters to different consumer preferences and therapeutic needs. CDMOs that specialize in these formulations can develop products that enhance user experience and improve treatment adherence. The formulation capabilities of creams and lotions facilitate the development of combination products that deliver multiple therapeutic benefits. This is particularly advantageous in treating complex conditions, as multi-functional products can address various symptoms simultaneously.

The increasing prevalence of skin disorders and the growing popularity of skincare products are driving demand for creams and lotions in the semi-solid CDMO market. This trend is supported by heightened consumer awareness regarding skin health and the efficacy of topical treatments. The rising prevalence of dermatological conditions, such as acne, dermatitis, and psoriasis, is creating a surge in demand for effective topical treatments. Pharmaceutical companies are increasingly focusing on the development of creams and lotions to address these conditions, leading to greater reliance on CDMOs for manufacturing. The global cosmetics industry is experiencing significant growth, with an increasing number of consumers seeking high-quality skincare products. This demand is driving the development of innovative creams and lotions, creating opportunities for CDMOs specializing in semi-solid formulations. As consumers become more informed about the benefits of active ingredients in skincare products, there is a growing preference for formulations that deliver visible results. CDMOs that can offer scientifically backed, effective creams and lotions are well-positioned to capture this market.

Based on region, The Asia Pacific region is experiencing rapid market growth. The Asia Pacific pharmaceutical market is one of the largest in the world and is expected to continue growing at a significant rate. This expansion drives demand for CDMO services, particularly for semi-solid products like creams, gels, and ointments. Countries such as India, China, and Southeast Asian nations are emerging as key players in the pharmaceutical landscape. The increasing number of domestic pharmaceutical companies seeking to enhance their product offerings will lead to a greater reliance on CDMOs for semi-solid formulations. Many governments in the region are emphasizing self-sufficiency in pharmaceutical production. This focus on local manufacturing capabilities will lead to an uptick in demand for CDMO services.

The increasing consumer awareness regarding skincare and the growing prevalence of dermatological conditions are driving demand for semi-solid formulations across Asia Pacific. With a rise in skin-related ailments, there is an increasing focus on effective topical treatments. Semi-solid formulations are particularly well-suited for addressing conditions such as eczema, acne, and psoriasis, prompting pharmaceutical companies to invest in their development. The cosmetics market in Asia Pacific is experiencing significant growth, driven by a rising middle class and increasing consumer spending on beauty products. This trend is leading to higher demand for creams and lotions, which in turn boosts the semi-solid CDMO market. The shift towards personalized medicine in the region also fuels demand for semi-solid formulations. CDMOs can provide customized solutions that cater to individual patient needs, further enhancing the attractiveness of semi-solid products. Asia Pacific CDMOs are increasingly investing in advanced manufacturing technologies and facilities, positioning themselves as competitive players in the global market. Investments in cutting-edge technologies, such as automation, robotics, and smart manufacturing, enhance production efficiency and quality. CDMOs in the region that leverage these advancements can offer superior semi-solid formulations that meet stringent regulatory standards. The ability to scale production and adapt to changing market demands is crucial in the semi-solid CDMO market. Asia Pacific CDMOs are improving their manufacturing capabilities to provide flexible production options that align with the needs of pharmaceutical companies. Many Asia Pacific countries offer cost advantages in manufacturing, including lower labor costs and favorable economic conditions. This cost competitiveness attracts global pharmaceutical companies looking to outsource their production needs to CDMOs in the region.

Major companies operating in Global Semi-Solid CDMO Market are:

• The Lubrizol Corporation
• Cambrex Corporation
• Contract Pharmaceuticals Limited
• Bora Pharmaceuticals
• Ascendia Pharmaceuticals
• Pierre Fabre group
• Piramal Pharma Limited
• DPT Laboratories, LTD
• LGM Pharma
• Pace Analytical Services, LLC

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The Global Semi-Solid CDMO market is poised for substantial growth, driven by increasing demand for semi-solid formulations, advancements in formulation technologies, and a strategic shift towards outsourcing among pharmaceutical companies. With regions like Asia Pacific leading the charge in market expansion, driven by a burgeoning pharmaceutical sector and supportive regulatory environments, CDMOs that prioritize innovation, quality, and customization will be well-positioned to capitalize on emerging opportunities. As the landscape continues to evolve, collaboration between pharmaceutical companies and CDMOs will be crucial for developing effective, patient-centered solutions that meet the complex needs of the healthcare market. Companies that adapt to these trends and invest in their capabilities will thrive in this dynamic and competitive environment”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Semi-Solid CDMO Market - Global Industry Size, Share, Trends, Opportunity & Forecast Segmented By Route of Administration (Topical, Transdermal, Others), By Product (Ointments, Creams and Lotions, Pastes, Gels, Others), By Service (Contract Development, Contract Manufacturing), By End User (Pharmaceutical Companies, Biopharmaceutical Companies, Others), By Region, & Competition, 2019-2029F”, has evaluated the future growth potential of Global Semi-Solid CDMO Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Semi-Solid CDMO Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]